NCT05782192View on ClinicalTrials.gov

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

SAL067

SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)

DRUG

Alogliptin

Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)

DRUG

Placebo

placebo 6mg (2 tablet) and placebo 25mg (1 tablet)

Trial Locations (1)

510120

1. Sun Yat-sen Memorial Hospital, Sun Yat-sen University,, Guangzhou

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05782192 - SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Biotech Hunter | Biotech Hunter